Sequence of Therapy and Survival among Advanced Pancreatic Neuroendocrine Tumors (pNETs) Abstract #1899

Introduction: Therapy for advanced pNETs involves surgery (SG) and non-SG options, including liver ablation (ABL), systemic therapy (ST), somatostatin analogues (SSA). Optimal initial therapy is unknown.
Aim(s): We describe sequence of therapy for pNETs and survival differences between treatment cohorts.
Materials and methods: Sequential patients with advanced pNETs referred to the BC Cancer Agency between 2000-2013 and received at least one treatment modality were reviewed. SG included any resection of primary or distant disease; ST included chemo- and small molecule therapy, and peptide receptor radiotherapy.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Erica Tsang

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1471 Chemotherapy for Stage IV Sporadic Pancreatic Neuroendocrine Tumors (pNET): Are Partial Responses to Post-first Line Chemotherapy Predictable by Response/Type of First Line Chemotherapy?
Introduction: Three types of chemotherapy are recommended for stage IV pancreatic neuroendocrine tumors (pNETs): streptozocin (STZ)-, dacarbazine (DCZ)- and oxaliplatin (OX)-based. Whether cross resistance exists is unknown.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Medical Doctor Vincenzo Marotta
Authors: Marotta V, Malka D, Walter T, Do Cao C, ...
#628 Sequential Chemo-Radiation Therapy for Locally Advanced Neuroendocrine Carcinoma of Head and Neck
Introduction: Neuroendocrine carcinomas (NECs) of the head and neck are considered an infrequent clinico-pathological entity. Combined modality treatment represents an established therapeutic option for poorly differentiated forms where distant metastasis is a common pattern of failure.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Young Mi Seol
Authors: Seol Y M, ...
#1116 Streptozotocin Based Chemotherapy in Advanced G2 Pancreatic Neuroendocrine Tumors (PNET): Efficacy According to KI67 Index
Introduction: Streptozotocin (STZ) with fluorouracil (FU) or doxorubicin (DOX) is approved in well differentiated advanced pancreatic neuroendocrine tumors (PNET).
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: PhD Paula Jiménez-Fonseca
#1670 A Successful Case of Controlling the Multiple Distant Metastasis of Pancreatic G2 NET with Local Therapy Combined with Systemic Pharmacotherapy
Introduction: Several systemic pharmacotherapies could be applied to multiple metastatic pancreatic neuroendocrine tumor (PNET). However, we have not determined how to coordinate ‘local’ therapy such as salvage surgery and transarterial chemoembolization with systemic pharmacotherapies for these multiple metastatic PNET.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Clinical cases/reports
Presenting Author: Yuichiro Uchida
Authors: Uchida Y, Masui T, Kenzo N, Asahi S, ...
#1842 OPALINE Study: Observational Study in a Real-World Setting of the Systemic Treatment of Progressive Unresectable or Well-Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET).
Introduction: OPALINE Study focuses on patients with pNET. Two targeted therapies (TT) offer new options to treat these patients: mTORi (everolimus) and a multi-targeted inhibitor (sunitinib).
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Julie Grellier de Heaulme